Clinical data | |
---|---|
Other names | CGS-25248; ZY-15119 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H18ClN3O3 |
Molar mass | 335.79 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Cebaracetam (INNTooltip International Nonproprietary Name; developmental code names CGS-25248; ZY-15119) is an experimental drug of the racetam group described as a nootropic which was never marketed.
It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and is also a derivative of RGPU-95 (4-chlorophenylpiracetam). It is the analogue of RGPU-95 in which the terminal amide group has been replaced with a piperazin-2-one moiety. The mechanism of action of cebaracetam is undefined or unknown.
The drug was under development by Novartis for the treatment of cognition disorders by the 1990s but development was discontinued in 1995. It reached phase 2 clinical trials prior to its discontinuation.
References
- ^ "Cebaracetam". AdisInsight. 23 May 1995. Retrieved 1 October 2024.
- https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/stembook-2018.pdf
- Chollet D, Künstner P (June 1992). "Fast systematic approach for the determination of drugs in biological fluids by fully automated high-performance liquid chromatography with on-line solid-phase extraction and automated cartridge exchange. Application to cebaracetam in human urine". Journal of Chromatography. 577 (2): 335–340. doi:10.1016/0378-4347(92)80255-o. PMID 1400764.
- ^ "Cebaracetam". PubChem. Retrieved 1 October 2024.
Racetams | |
---|---|
Racetams |
|
Phenylpiracetams |
|
Racetam-like |
|
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |